tbuckley/cabot-search huggingface dataset:
426. dSLIM Immunomodulators Induce Anti- Tumor Responses Both In Vitro and In Vivo
Authors: Manuel Schmidt, Javier Cristobal, Astrid Sander, Bernadette Brzezicha, Sven A. Konig Merediz, Burghardt Wittig
Journal: Molecular Therapy (2006)

Cytosine-guanine (CpG) motifs containing oligonucleotides (ODN) are commonly used for immunomodulatory purpose in cancer therapy and for the treatment of allergic diseases since they resemble bacterial DNA and serve as |[ldquo]|danger signals|[rdquo]|. These CpG-ODNs promote predominately a TH1-response with secretion of IL-12 and IFN-|[gamma]|, In addition their broad potential includes activation of B-cell proliferation, monocyte stimulation and secretion of IgM and IL-6, and stimulation of plasmacytoid DC to produce IFN-|[alpha]|/-|[beta]| and thus |[gamma]||[delta]|T-cells and NK-cells to express CD69 and secrete IFN-|[gamma]|. Usually phosphorothioate (PS) modifications are to enhance the stability, but these are leading to several side-effects, like severe organ enlargements, morphological changes and immunosuppression in mice. We designed immunomodulatory molecules based on short covalently-closed dumbbell-like structures (dSLIM) to stabilize the DNA without the otherwise necessary PS-modification. To evaluate the anti-tumor effect of the dSLIM molecules we developed an in vitro anti-tumor assay. This assay uses supernatant from dSLIM-activated human PBMCs for incubation with tumor cells in vitro. We observed increased apoptosis and necrosis of the HT-29 tumor cell line after incubation with supernatant from dSLIM-treated PBMC which was significantly higher than the effect of supernatant from non-treated PBMC. In addition, supernatant from dSLIM- treated PBMC increased the expression of HLA-ABC on the tumor cells, a pre-requisite for tumor cell recognition by the immune system. These effects were confirmed with human HEK293 and murine Renca cell lines. Analyzing the effect with neutralizing antibodies to various apoptosis-related cytokines, we observed a crucial role of IFN-|[gamma]| but not IFN-|[alpha]| or TNF|[alpha]|. To investigate the anti-tumor effects of dSLIM in vivo, we employed a SKH1 murine model which is prone to spontaneous development of papillomas. Using chemicals for initiation and weekly promotion of de novo papilloma development we compared groups of weekly s.c. or i.p. dSLIM injections, respectively, with the PBS control group. The number ofpapilloma developing mice was significantly lower in the dSLIM groups and the total number of papillomas on all mice was reduced by approximately 50%. In conclusion, we showed that dSLIM immunomodulators exhibit potent anti-tumor effects in vitro and in vivo.
Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
Authors: Philipp D. le Coutre, Francis Giles, Andreas Hochhaus, Jane F. Apperley, Gert Ossenkoppele, Ariful Haque, Neil J. Gallagher, Michele Baccarani, Jorge Cortes, Hagop M Kantarjian
Journal: Blood (2008)
Patients with Lymphoma May Harbor Mutations of the Perforin Gene.
Authors: Rita Clementi, Franco Locatelli, Loic Dupre, Alberto Garaventa, Lorenzo Emmi, Marco Bregni, Graziella Cefalo, Antonia Moretta, Cesare Danesino, Margherita Comis, Andrea Pession, Ugo Ramenghi, Rita Maccario, Maurizio Arico’, Maria Grazia Roncarolo
Journal: Blood (2004)
Hepatocellular Carcinoma: The Role of Interventional Oncology
Authors: Matteo Donadon, Luigi Solbiati, Laura Dawson, Aisling Barry, Gonzalo Sapisochin, Paul D Greig, Shuichiro Shiina, Andrea Fontana, Guido Torzilli
Journal: Liver Cancer (2016)

Hepatocellular carcinoma (HCC) remains a major health issue because of its increasing incidence and because of the complexity of its management. In addition to the traditional potentially curative treatments, i.e., liver transplantation and surgical resection, other new and emerging local therapies have been applied with promising results.
Chronic Myelogenous Leukemia Cells Contribute to a Bone Marrow-Stroma in In Vivo NOD/SCID Mouse System.
Authors: Ryosuke Shirasaki, Haruko Tashiro, Yoko Oka, Toshihiko Sugao, Nobu Akiyama, Kazuo Kawasugi, Naoki Shirafuji
Journal: Blood (2009)
Preoperative telephone consultation does not decrease patient anxiety before Mohs micrographic surgery
Authors: Joseph F. Sobanko, Diego Da Silva, Zelma C. Chiesa Fuxench, Badri Modi, Thuzar M. Shin, Jeremy R. Etzkorn, Sara S. Samimi, Karolyn A. Wanat, Christopher J. Miller
Journal: Journal of the American Academy of Dermatology (2016)
A Novel Synthetic GMCSF and MCP3 Fusion Cytokine Induces IL10-Producing B Cells with Immune Modulatory Properties on Antigen Presentation and Th17 Development
Authors: Hsiang-Chuan (Jeremy) Hsieh, Patrick Williams, Moutih Rafei, Elena Birman, Yoon Now Young, Jacques Galipeau
Journal: Blood (2010)
Identification of Integrin β3 L718P Mutation in a Pedigree with Autosomal Dominant Macrothrombocytopenia
Authors: Yoshiyuki Kobayashi, Hirotaka Matsui, Akinori Kanai, Miyuki Tsumura, Satoshi Okada, Mizuka Miki, Kazuhiro Nakamura, Shinji Kunishima, Toshiya Inaba, Masao Kobayashi
Journal: Blood (2012)
Purinergic Signaling Modulates Human Bone Marrow-Derived Mesenchymal Stem Cells Function.
Authors: Valentina Salvestrini, Davide Ferrari, Sara Gulinelli, Luisa Caione, Wanda Piacibello, Roberta Zini, Marilena Ciciarello, Rossella Manfredini, Giovanna Lucchetti, Sergio Ferrari, Francesco Di Virgilio, Roberto M Lemoli
Journal: Blood (2009)
CEBPA Methylation and Notch1 Mutations Are Common in Immature T-ALLs but Not M0 AML and Cosegregate with TCRG Rearrangement and the TCRgd Lineage.
Authors: L. Terriou, R. Ben Abdelali, C. Roumier, J. de Vos, P. Cornillet, O. Nibourel, K. Beldjord, H. Dombret, G. Leverger, V. Asnafi, Claude Preudhomme, E. Macintyre
Journal: Blood (2007)
Cytotoxic Effect of R-Etodolac (SDX-101) in Combination with Purine Analogues or Monoclonal Antibodies on Ex-Vivo B-Cell Chronic Lymphocytic Leukemia Cells.
Authors: Pawel Robak, Anna Linke, Barbara Cebula, Lorenzo M. Leoni, Tadeusz Robak, Piotr Smolewski
Journal: Blood (2005)
Defect in Ribosome Biogenesis Contributes to Impaired Megakaryopoiesis in Primary Myelofibrosis
Authors: Laure Gilles, Ahmet Dirim Arslan, Katerina Konstantinoff, Maureen McNulty, Lasho Terra, Animesh Pardanani, Brady L Stein, Isabelle Plo, William Vainchenker, Leonidas Platanias, Ayalew Tefferi, John D Crispino
Journal: Blood (2014)
Abstract 3249: Recurrent 3p21 deletion in head and neck squamous cell carcinoma identifies SEMA3F as an anti-lymphangiogenic metastasis suppressor gene
Authors: Colleen L. Doçi, Constantinos M. Mikelis, Michail S. Lionakis, Alfredo A. Molinolo, J Silvio Gutkind
Journal: Cancer Research (2015)

Abstract Head and neck squamous cell carcinomas (HNSCC) often metastasize to locoregional lymph nodes, and lymph node involvement represents one of the most important prognostic factors of poor clinical outcome. HNSCC are remarkably lymphangiogenic and represent a clear example of a cancer that utilizes the lymphatic vasculature for malignant dissemination; however, the molecular mechanisms underlying lymphangiogenesis in HNSCC is still poorly understood. Of interest, we found that an axon guidance molecule, Semaphorin 3F (SEMA3F), is among the top 1% underexpressed genes in HNSCC, and that genomic loss of SEMA3F correlates with increased metastasis and decreased survival. SEMA3F acts on its co-receptors, plexins and neuropilins, among which neuropilin-2 (NRP2) is highly expressed in lymphatic endothelial cells (LECs) but not in oral epithelium and most HNSCCs. We show that recombinant SEMA3F promotes LEC collapse and potently inhibits lymphangiogenesis in vivo. By reconstituting all possible plexin and neuropilin combinations, we found that SEMA3F acts through multiple receptors, but predominantly requires NRP2 to signal in LECs. Using orthotopic HNSCC metastasis mouse models, we provide direct evidence that SEMA3F re-expression diminishes lymphangiogenesis and lymph node metastasis. Furthermore, analysis of a large tissue collection revealed that SEMA3F is progressively lost during HNSCC progression, concomitant with increased tumor lymphangiogenesis. SEMA3F is localized to 3p21, an early and frequently deleted locus in HNSCC and many other prevalent human malignancies. Thus, SEMA3F may represent an antilymphangiogenic metastasis suppressor gene widely lost during cancer progression, hence serving as a prognostic biomarker and an attractive target for therapeutic intervention to halt metastasis. Citation Format: Colleen L. Doçi, Constantinos M. Mikelis, Michail S. Lionakis, Alfredo A. Molinolo, J Silvio Gutkind. Recurrent 3p21 deletion in head and neck squamous cell carcinoma identifies SEMA3F as an anti-lymphangiogenic metastasis suppressor gene. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3249. doi:10.1158/1538-7445.AM2015-3249
ACTR-09. CLINICAL RESULTS OF THE EORTC RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1ST RECURRENCE OF GRADE II OR III GLIOMA WITHOUT 1p/19q CO-DELETION
Authors: Martin van den Bent, Paul Clement, Filip Vos, Michael Platten, Paul Mulholland, Martin Taphoorn, Joanne Lewis, Thierry Gorlia, Vassilis Golfinopoulos, Ahmed Idbaih, Olivier Chinot
Journal: Neuro-Oncology (2016)

The role of bevacizumab in recurrent grade II and III gliomas is unclear. Similar to glioblastoma, uncontrolled studies have shown promising response rates but controlled studies are not available. We conducted a randomized phase II study, in which we investigated the addition of bevacizumab (BEV) to temozolomide (TMZ) in patients with tumors without 1p/19q co-deletion. Eligible were patients with a locally diagnosed grade II or III glioma without 1p/19q co-deletion, with a first and enhancing recurrence after initial radiotherapy. Prior chemotherapy (either TMZ or PCV regimen) was allowed provided patients were at least 6 months off treatment. Patients were treated with either TMZ day 1-5 200 mg/m2 for twelve cycles (arm A), or with the same TMZ regimen in combination with BEV 10 mg/kg every 2 weeks (arm B) until progression. Response was evaluated every three months using RANO criteria. Primary endpoint was the overall survival rate at 12 months (OS12). An A’Hern design was used, 144 patients would have to be randomized to reject the H0 hypothesis of 50% in favour of the H1 hypothesis of 65%. Analysis of MGMT status and IDHmutational status is part of the study design (trial nr: NCT01164189). Between Feb 8, 2011 and July 31, 2015 155 patients were randomized. Baseline characteristics of both groups were similar. Median age was 44 years, 53% were initially diagnosed with a grade II tumor, and 27% of patients had received prior chemotherapy. In August 2016, OS data will be mature and the clinical outcome will be analyzed. At the meeting the mature OS results of this randomized phase II trial will be presented.
Regulation of multidrug resistance by microRNAs in anti-cancer therapy
Authors: Xin An, Cesar Sarmiento, Tao Tan, Hua Zhu
Journal: Acta Pharmaceutica Sinica B (2016)

Multidrug resistance (MDR) remains a major clinical obstacle to successful cancer treatment. Although diverse mechanisms of MDR have been well elucidated, such as dysregulation of drugs transporters, defects of apoptosis and autophagy machinery, alterations of drug metabolism and drug targets, disrupti on of redox homeostasis, the exact mechanisms of MDR in a specific cancer patient and the cross-talk among these different mechanisms and how they are regulated are poorly understood. MicroRNAs (miRNAs) are a new class of small noncoding RNAs that could control the global activity of the cell by post-transcriptionally regulating a large variety of target genes and proteins expression. Accumulating evidence shows that miRNAs play a key regulatory role in MDR through modulating various drug resistant mechanisms mentioned above, thereby holding much promise for developing novel and more effective individualized therapies for cancer treatment. This review summarizes the various MDR mechanisms and mainly focuses on the role of miRNAs in regulating MDR in cancer treatment.
Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT
Authors: Curly Morris, Simona Iacobelli, Gosta Gahrton, Laurent Garderet, Mary Drake, Anja van Biezen, Mohamad Mohty, Didier Blaise, Xavier Poiré, Marie José Kersten, Noel-Jean Milpied, Stig Lenhoff, Nigel H. Russell, J.ürgen Finke, T. M. de Witte
Journal: Blood (2011)
Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism.
Authors: Razvan Diaconescu, Wendy Leisenring, Christoph Kahl, Mohamed Sorror, Eustacia Zellmer, Michael Maris, Marie-Terese Little, Rainer Storb
Journal: Blood (2004)
Pre- vs. Post-National Coverage Determination (NCD) Blood Utilization and Hemoglobin Values among Medicare Patients Treated with Erythropoietic-Stimulating Agents (ESAs) for Chemotherapy-Induced Anemia (CIA)
Authors: Tanya Burton, Kay Larholt, Elizabeth Apgar, Chris Pashos, Brahim Bookhart, Mitra Corral, Catherine Tak Piech, R. Scott Mckenzie
Journal: Blood (2008)
Non-Proteolytic Regulation of the Multimerization of Von Willebrand Factor By ADAMTS13 Based on a Novel Cysteine Thiol Redundancy
Authors: Hanspeter Rottensteiner, Susanna Skalicky, Birgit Seyfried, Stefan Kaufmann, Christian Fiedler, Meinhard Hasslacher, Jing-fei Dong, X. Long Zheng, Barbara Plaimauer, Friedrich Scheiflinger
Journal: Blood (2015)
Treatment with an Anti-C3b/iC3b Monoclonal Antibody as an Adjuvant to Rituximab Enhances the Killing of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Cells.
Authors: Wu Peng, Xin Zhang, Juan Li, Giorgio Inghirami, Kenichi Takeshita, Andrew Pecora, Steve E. Pincus, Linda L. Nardone, Leslie S. Casey, George L. Spitalny
Journal: Blood (2004)
A Phase II Study of Denileukin Diftitox (ONTAKR) in Patients with Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia.
Authors: Philip Kuriakose, Francesco Turturro, Jesus G. Berdeja, Robert Kerr, Asha Surendranathan, Jennifer Black, Arthur E. Frankel
Journal: Blood (2004)
Relevance of Chloride Binding to Von Willebrand Factor in Type 2B Von Willebrand Disease Patients.
Authors: Luciano Baronciani, Flora Peyvandi, Margherita Punzo, Maria T. Canciani, Enrico Di Stasio, Augusto B. Federici, Pier M. Mannucci, Raimondo De Cristofaro
Journal: Blood (2008)
Functionalized Carbon Nanotubes Increase the Viability of Post-Thaw Cord Blood Cells and Enhance the Overall Hematopoietic Progenitor Cell Expansion in Ex Vivo Culture
Authors: Pat PY Chu, Sudipto Bari, Leong U Ling, Yee W Chen, Andrea Lim, Xiubo Fan, Florence PH Gay, Justina ML Ang, Gigi NC Chiu, William YK Hwang
Journal: Blood (2011)
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis
Authors: Kate T Simms, Jean-François Laprise, Megan A Smith, Jie-Bin Lew, Michael Caruana, Marc Brisson, Karen Canfell
Journal: The Lancet Public Health (2016)

BackgroundFirst generation bivalent and quadrivalent human papillomavirus (HPV) vaccines have been introduced in most developed countries. A next generation nonavalent vaccine (HPV9) has become available, just as many countries are considering transitioning from cytology-based to HPV-based cervical screening. A key driver for the cost-effectiveness of HPV9 will be a reduction in screen-detected abnormalities and surveillance tests. We aimed to evaluate the cost-effectiveness of HPV9 in Australia, a country with HPV vaccination of both sexes that is transitioning to 5-yearly HPV-based screening.MethodsWe used Policy1-Cervix and HPV-ADVISE—two dynamic models of HPV transmission, vaccination, and cervical screening—to estimate the cost-effectiveness of HPV9 versus quadrivalent vaccine (HPV4), assuming lifelong vaccine protection, two vaccine doses, and that additional costs were incurred in girls only. Policy1-Cervix was used to estimate the lifetime risk of cervical cancer diagnosis and death. Probabilistic sensitivity analysis of the cost-effectiveness outcomes was done with both models, and results are presented as the median and 10th to 90th percentiles of simulation runs (referred to as 80% uncertainty intervals [UIs]).FindingsCompared with cytology-based screening, HPV screening is predicted to reduce lifetime risk of cervical cancer diagnosis by 18% and of death by 20%, even in unvaccinated cohorts. Under base-case assumptions (lifelong protection, full efficacy at two doses), HPV4 will provide a further reduction in diagnosis of 54% and in death of 53% and HPV9 will provide a further reduction in both diagnosis and death of 11%, compared with cytology-based screening in unvaccinated cohorts. For HPV9 to remain a cost-effective alternative to HPV4, the incremental cost per dose in girls should not exceed a median of AUS$35·99 (80% UI 28·47–41·18) with Policy1-Cervix or AUS$22·74 (15·49–34·45) with HPV-ADVISE, at a willingness-to-pay threshold of AUS$30 000 per quality-adjusted life-year.InterpretationDiffering methods and assumptions led to some differences in the estimates produced by the two models. However, on the basis of median results, HPV9 will be a cost-effective alternative to HPV4 if the additional cost per dose is AUS$23–36 (US$18–28). These results will be important when determining the optimum price of the vaccine in Australia.FundingNational Health and Medical Research Council, Australia.
Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)
Authors: Marta Bruno Ventre, Giovanni Donadoni, Alessandro Re, Michele Spina, Chiara Cattaneo, Luca Fumagalli, Silvia Mappa, Silvia Govi, Giuseppe Rossi, Umberto Tirelli, Andrés JM Ferreri
Journal: Blood (2011)
Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma
Authors: Mohamad Sobh, Stephane Morisset, Taoufik Guilli, Sophie Ducastelle-Lepretre, Fiorenza Barraco, Youcef Chelghoum, Giovanna Cannas, Xavier Thomas, Aline Praire, Helene Labussiere, Franck E Nicolini, Colette Chapuis-Celier, Mauricette Michallet
Journal: Blood (2010)
<i>TP53</i> and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas
Authors: Aden K Chan, Ying Mao, Ho-Keung Ng
Journal: New England Journal of Medicine (2016)

Deletion of chromosome arms 1p and 19q and mutations in IDH and TERT define prognostic subgroups of low-grade gliomas. Gliomas without these lesions (triple-negative gliomas) are more common in China, often have TP53 mutations, and are associated with a worse prognosis.
RAB14 and RAB5 Gtpases Regulate Human Erythropoiesis, Potentially Via Opposing Roles in Endosomal Recycling
Authors: MinJung Kim, Tami J. Kingsbury, Wen-Chih Cheng, Yee Sun Tan, Brittany M. Taylor, Sampada Koshatwar, Curt I. Civin
Journal: Blood (2015)
A Novel Multi-Gene Expression Array Allows Highly Sensitive Detection Of Minimal Residual Disease and Predicts Relapse Outcomes In Acute Myeloid Leukemia
Authors: Meghali Goswami, Katherine S. McGowan, Kit Lu, Sandhya R. Panch, Nancy F. Hensel, Minoo Battiwalla, A. John Barrett, Christopher S. Hourigan
Journal: Blood (2013)
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
Authors: Philippe Moreau, Asher Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, David Darden, Lura Morris, Jeremy Ross, Ahmed H Salem, Wijith Munasinghe, Ming Zhu, Joel Leverson, Paulo Maciag, Sari Heitner Enschede, Maria Verdugo, Rod A. Humerickhouse, Simon Harrison
Journal: Blood (2015)
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Authors: P. Bidoli, F. Cappuzzo, A. Favaretto, O. Alabiso, M. Tiseo, A. Chella, V. Gebbia, L. Pizzuti, L. Paz-Ares, M. Perol, E. Garon, P. Lee, A. Zimmermann, G. Cuyun Carter, M.R. Migliorino
Journal: Annals of Oncology (2015)
Possible Role Of Circulating Adenine Nucleotides and Platelet Activation In The Pathogenesis Of Sickle Cell Disease: Observations In a Murine Model
Authors: Kousaku Ohno, Hisako Tanaka, Naozumi Samata, Tomizawa Atsuyuki, Makoto Mizuno, Joseph A. Jakubowski, Atsuhiro Sugidachi
Journal: Blood (2013)
Expression Profile Signature to Predict Response to Bortezomib and Dexamethasone Combination Therapy in Newly-Diagnosed Myeloma: Moving towards Prospective Prediction
Authors: Nikhil C. Munshi, Cheng Li, Stephane Minvielle, Samir B Amin, Philippe Moreau, Florence Magrangeas, Kenneth C Anderson, Herve Avet-Loiseau
Journal: Blood (2008)
5′-ABL Gene Deletion on Derivative Chromosome 9 Detected by FISH: Prognostic Significance in CML Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Naeem A. Chaudhri, Mahmoud D. Aljurf, Entezam A. Sahovic, Fahad Almhareb, Fahad Al-Sharif, Hazzaa Al-Zahrani, Hamad Al-Omar, Ali Al-Shanqeeti, Syed Zaidi, Manzur Morshed, Khalid Al-Anazi, Ibrahim El-Hassan, Mohammad Al-Lahham, Mohammad A. Iqbal
Journal: Blood (2005)
Prognostic Significance of Gelsolin and MMP12 in Langerhans Cell Histiocytosis.
Authors: Sun Young Kim, Hee Jin Kim, Keun Wook Bae, Ho Joon Im, Ji Yoon Kim, Dae-Chul Jeong, Mee Jeong Lee, Eun Sil Park, Jong Jin Seo
Journal: Blood (2009)
Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes
Authors: Francesca Schieppati, Erin P. Demakos, Odchimar Rosalie-Reissig, Shyamala C. Navada, Lewis R. Silverman
Journal: Blood (2015)